KidneyIntelX found effective in patients with early stage disease
Click Here to Manage Email Alerts
Investigators found the diabetic kidney disease progression test KidneyIntelX, by RenalytixAI plc, successfully risk stratified a large cohort of patients for disease progression, according to a press release.
In a large multi-national cohort of the Canagliflozin Cardiovascular Assessment Study (CANVAS), David W. Lam, MD, medical director at Mount Sinai Clinical Diabetes Institute, and colleagues applied the KidneyIntelX composite risk score to 1,325 patients with prevalent diabetic kidney disease and type 2 diabetes. A score between 5 and 45 was considered low risk, between 50 and 85 was considered immediate risk and 90, 95 and 100 were considered high risk.
“The new data from CANVAS supports primary care physicians using the KidneyIntelX score to risk stratify and make informed care decisions with their patients,” Lam said in the press release. “The results also advance the concept that there is most to be gained from early stage intervention and the protective effects of SGLT2i on kidney function decline in those that score as highest risk for progression with KidneyIntelX.”
According to the release, the authors’ results exhibited comparable risk stratification to other validation studies, with high-risk patients having an eight-fold higher rate of disease progression compared with low-risk patients. However, the Kidney Disease: Improving Global Outcomes risk classification tool linked high-risk patients with only a 2.5-fold higher rate of disease progression.
Among the patients in the study, an average of 26% scored as high risk, 11% scored as intermediate risk and 3% scored as low risk using KidneyIntelX.
According to the release, Lam presented the study results at the International Society of Nephrology World Congress of Nephrology 2021, which was held as a virtual meeting.
Collapse
Read more about
Click Here to Manage Email Alerts